Leerink Partners Downgrades Halozyme Therapeutics to Market Perform, Raises Price Target to $117
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsDowngradesPrice Target
Leerink Partners analyst David Risinger downgrades Halozyme Therapeutics (NASDAQ:HALO) from Outperform to Market Perform and raises the price target from $110 to $117.
Leerink Partners analyst David Risinger downgrades Halozyme Therapeutics (NASDAQ:HALO) from Outperform to Market Perform and raises the price target from $110 to $117.